The Synthesis and Evaluation of C7-Substituted α-Tetralone Derivatives as Inhibitors of Monoamine Oxidase

Chemical Biology and Drug Design

Volumn 86, Issue 4, 2015, Pages 895-904

  Legoabe, Lesetja J ^a   Petzer, Anél ^a   Petzer, Jacobus P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

competitive; dialysis; inhibition; monoamine oxidase; reversible; tetralone

Indexed keywords

1 TETRALONE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; LAZABEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; AMINE OXIDASE (FLAVIN CONTAINING); TETRALIN DERIVATIVE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; CRYSTALLIZATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME SUBSTRATE; HYDROGEN BOND; IC50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; PARKINSON DISEASE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THERAPY EFFECT; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; SYNTHESIS;

HUMANS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRALONES;

EID: 84942526419     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12508     Document Type: Article

References (32)

1. Olanow C.W., Stern M.B., Sethi K., (2009) The scientific and clinical basis for the treatment of Parkinson disease. Neurology; 72 (21 Suppl 4): S1-S36.
2. Carlsson A., (2002) Treatment of Parkinson's with L-Dopa. The early discovery phase, and a comment on current problems. J Neural Transm; 109: 777-787.
3. Pedrosa D.J., Timmermann L., (2013) Review: management of Parkinson's disease. Neuropsychiatr Dis Treat; 9: 321-340.
4. Talati R., Baker W.L., Patel A.A., Reinhart K., Coleman C.I., (2009) Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Int J Clin Pract; 63: 613-623.
5. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., Marekm K., Parkinson Study Group. (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med; 351: 2498-2508.
6. Youdim M.B., Edmondson D., Tipton K.F., (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci; 7: 295-309.
7. Shoulson I., Oakes D., Fahn S., Lang A., Langston J.W., LeWitt P., Olanow C.W., Penney J.B., Tanner C., Kieburtz K., Rudolph A., Parkinson Study Group. (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol; 51: 604-612.
8. Fernandez H.H., Chen J.J., (2007) Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy; 27: 174S-185S.
9. Finberg J.P., Wang J., Bankiewicz K., Harvey-White J., Kopin I.J., Goldstein D.S., (1998) Increased striatal dopamine production from L-Dopa following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm Suppl; 52: 279-285.
10. Pålhagen S., Heinonen E.H., Hägglund J., Kaugesaar T., Kontants H., Mäki-Ikola O., Palm R., Turunen J., (1998) Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology; 51: 520-525.
11. Shih J.C., Chen K., Ridd M.J., (1999) Monoamine oxidase: from genes to behavior. Annu Rev Neurosci; 22: 197-217.
12. Fowler C.J., Wiberg A., Oreland L., Marcusson J., Winblad B., (1980) The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm; 49: 1-20.
13. Kalaria R.N., Mitchell M.J., Harik S.I., (1988) Monoamine oxidases of the human brain and liver. Brain; 111: 1441-1451.
14. Riachi N.J., Harik S.I., (1992) Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys. Exp Neurol; 115: 212-217.
15. Collins G.G., Sandler M., Williams E.D., Youdim M.B., (1970) Multiple forms of human brain mitochondrial monoamine oxidase. Nature; 225: 817-820.
16. Fowler J.S., Volkow N.D., Wang G.J., Logan J., Pappas N., Shea C., MacGregor R., (1997) Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging; 18: 431-435.
17. Youdim M.B., Weinstock M., (2004) Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology; 25: 243-250.
18. Schwartz T.L., (2013) A neuroscientific update on monoamine oxidase and its inhibitors. CNS Spectr; 18 (Suppl 1): 25-32.
19. Lum C.T., Stahl S.M., (2012) Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression. CNS Spectr; 17: 107-120.
20. Costa F.H., Rosso A.L., Maultasch H., Nicaretta D.H., Vincent M.B., (2012) Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr; 70: 617-620.
21. Da Prada M., Zürcher G., Wüthrich I., Haefely W.E., (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl; 26: 31-56.
22. Bonnet U., (2003) Moclobemide: therapeutic use and clinical studies. CNS Drug Rev; 9: 97-140.
23. Provost J.C., Funck-Brentano C., Rovei V., D'Estanque J., Ego D., Jaillon P., (1992) Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther; 52: 384-393.
24. Legoabe L.J., Petzer A., Petzer J.P., (2014) α-Tetralone derivatives as inhibitors of monoamine oxidase. Bioorg Med Chem Lett; 24: 2758-2763.
25. Shoup T.M., McCauley J.P., Lee D.F. Jr, Chen R., Normandin M.D., Bonab A.A., El Fakhri G., Vasdev N., (2014) Synthesis of the dopamine D2/D3 receptor agonist (+)-PHNO via supercritical fluid chromatography: preliminary PET imaging study with [3-11C]-(+)PHNO. Tetrahedron Lett; 55: 682-685.
26. Novaroli L., Reist M., Favre E., Carotti A., Catto M., Carrupt P.A., (2005) Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg Med Chem; 13: 6212-6217.
27. Strydom B., Malan S.F., Castagnoli N. Jr, Bergh J.J., Petzer J.P., (2010) Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem; 18: 1018-1028.
28. Petzer A., Pienaar A., Petzer J.P., (2013) The inhibition of monoamine oxidase by esomeprazole. Drug Res (Stuttg); 63: 462-467.
29. Petzer A., Pienaar A., Petzer J.P., (2013) The interactions of caffeine with monoamine oxidase. Life Sci; 93: 283-287.
30. Son S.Y., Ma J., Kondou Y., Yoshimura M., Yamashita E., Tsukihara T., (2008) Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci USA; 105: 5739-5744.
31. Binda C., Wang J., Pisani L., Caccia C., Carotti A., Salvati P., Edmondson D.E., Mattevi A., (2007) Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem; 50: 5848-5852.
32. Legoabe L.J., Petzer A., Petzer J.P., (2012) Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives. Eur J Med Chem; 49: 343-353.